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BCRP/ABCG2 mediates efflux of drugs and xenobi-
otics. BCRP was expressed in Pichia pastoris, puri-
fied to > 90% homogeneity, and subjected to two-
dimensional (2D) crystallization. The 2D crystals
showed a p121 symmetry and projection maps
were determined at 5 A˚ resolution by cryo-electron
microscopy. Two crystal forms with and without
mitoxantrone were observed with unit cell dimen-
sions of a = 55.4 A˚, b = 81.4 A˚, g = 89.8, and a =
57.3 A˚, b = 88.0 A˚, g = 89.7, respectively. The projec-
tion map without mitoxantrone revealed an asym-
metric structure with ring-shaped density features
probably corresponding to a bundle of transmem-
brane a helices, and appeared more open and
less symmetric than the map with mitroxantrone.
The open and closed inward-facing forms of BCRP
were generated by homologymodeling, representing
the substrate-free and substrate-bound conforma-
tions in the absence of nucleotide, respectively.
These models are consistent with the experimentally
observed conformational change upon substrate
binding.
INTRODUCTION
Resistance to anticancer agents is a major cause of chemother-
apeutic failure in cancer. One mechanism involves active extru-
sion of drugs out of cells by membrane transport proteins result-
ing in cellular drug levels below that required for cytotoxicity.
Clinical and in vitro cell-based studies have shown that multidrug
resistance is often associated with increased expression of
one or more transport proteins belonging to the ATP-binding
cassette (ABC) transporter superfamily which use the energy
provided by ATP binding and hydrolysis at their nucleotide
binding domains (NBDs) to transport substrates across the
cell membrane (Sarkadi et al., 2006). Themost important eukary-
otic ABC transporters involved in multidrug resistance are
P-glycoprotein (P-gp/ABCB1), multidrug resistance protein 1482 Structure 18, 482–493, April 14, 2010 ª2010 Elsevier Ltd All righ(MRP1/ABCC1), and breast cancer resistance protein (BCRP/
ABCG2).
The 75 kDa human BCRP is a polytopic plasma membrane
transport protein that has been detected in many drug-resistant
cell lines, solid tumors, and hematological malignancies (Robey
et al., 2009). Transport studies using BCRP-overexpressing
intact cells or BCRP-enriched plasma membrane vesicles have
established that BCRP can actively transport a broad spectrum
of substrates, ranging from hydrophobic chemotherapeutics
to hydrophilic anionic conjugated endo- and xenobiotics (Mao
and Unadkat, 2005; Polgar et al., 2008). BCRP is highly
expressed in organs important for the absorption (the small
intestine), distribution (e.g., the blood-brain and placental bar-
riers), and elimination (e.g., the liver and kidney) of drugs (Malie-
paard et al., 2001), and plays an important role in drug disposi-
tion (Mao and Unadkat, 2005; Robey et al., 2009).
ABC transporters usually consist of two hydrophobic trans-
membrane domains (TMDs) with 12 transmembrane (TM)
a helices and two hydrophilic NBDs for substrate and ATP
binding, respectively (Sarkadi et al., 2006). P-gp and MRP1 are
arranged in two repeated halves with 12 and 17 TM a helices,
respectively, forming a funnel facing the outside of cell mem-
brane (Loo andClarke, 2001;Rosenberg et al., 2005) and a higher
resolution structure of P-gp was recently described (Aller et al.,
2009). In contrast, BCRP is a half ABC transporter with one
NBD followed by one TMD (Polgar et al., 2008). The most recent
topology analysis suggests that the TMD of BCRP consists of
6 TM a helices (Wang et al., 2008). Hence, BCRP appears to
require homodimerization to exert its activity and a homotetra-
meric configuration of BCRP has been proposed (McDevitt
et al., 2006; Xu et al., 2004). The substrate specificity of BCRP
is overlapping with, but distinct from that of P-gp and MRP1
(Mao and Unadkat, 2005; Polgar et al., 2008). TM6 and TM12
of P-gp are involved in drug binding (Loo and Clarke, 2001).
It has been shown that arginine at position 482 of BCRP,
which is located within TM3 near the cytosolic membrane inter-
face, is critical for substrate specificity and transport activity,
suggesting that an alternative drug-binding mechanism is
applicable for BCRP (Honjo et al., 2001; Ozvegy-Laczka et al.,
2005).
Structural features responsible for such differences in drug-
binding and transport mechanisms of different ABC transporters
are yet not known. Indeed, little is known about the structurets reserved
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Projection Structures of Human BCRP/ABCG2of BCRP, although an atomic model of BCRP was recently pre-
dicted by homology modeling based on the crystal structure of
the bacterial multidrug exporter Sav1866, which suggested
that BCRP had multiple drug-binding sites (Hazai and Bikadi,
2008). We have previously reported functional expression of
human BCRP at a relatively high level in Pichia pastoris (Mao
et al., 2004). BCRP expressed in Pichia pastoris was active in
transporting its substrate estrone 3-sulfate and in hydrolyzing
ATP. This suggested that Pichia pastoris could be used to over-
express and purify BCRP for structural analysis. In this study,
we have purified BCRP from Pichia pastoris, facilitated by a
10-histidine tag attached to the COOH-terminus of the trans-
porter. Electron crystallography has emerged as a powerful
tool to determine the structures of membrane proteins from 2D
crystals, including that of P-gp (Rosenberg et al., 2005) and
several at atomic resolutions (Gonen et al., 2005; Holm et al.,
2006; Kuhlbrandt et al., 1994). We have captured structural infor-
mation of BCRP from 2D crystals that were grown in the pres-
ence and absence of the substrate drug mitoxantrone, analyzed
by cryo-electron microscopy (cryo-EM), and projection struc-
tures determined at 5 A˚ resolution. Conformational changes
were observed in 2D crystals grown in the absence and pres-
ence of mitoxantrone. Analysis and homology modeling of the
differences between these structural states also indicated
a significant conformational change. This structural information
provides a basis for further structural and mechanistic analysis
of BCRP and related ABC proteins.
RESULTS AND DISCUSSION
Production and Characterization of BCRP Expressed
in Pichia pastoris
Recombinant full-length human BCRP with a 10-histidine tag
attached at the COOH-terminus of the protein was expressed
in Pichia pastoris as previously described (Mao et al., 2004).
The expression of BCRP in Pichia pastoris was detected by
immunoblotting of the microsomes with the monoclonal anti-
body BXP-21 and a major immunoreactive band of approxi-
mately 65 kDa was observed (Figure 1A). Solubilization of
BCRP from crude microsome membranes was evaluated using
several detergents. Approximately 50%of BCRPwas solubilized
by lysophosphatidylcholine (LPC) at a LPC/protein ratio (mg/mg)
of more than 5. N-dodecyl b-D maltoside (DDM) wasmore effec-
tive than LPC, which solubilized more than 90% of BCRP at
a relatively low DDM/protein ratio (mg/mg) of 2 at 4C.
The detergent extract of BCRP was subjected to Ni2+-NTA
affinity chromatography. Comparison of the detergent-extract
and flow through suggested that more than 70% of the DDM-
solubilized BCRP bound to Ni2+-NTA as visualized on silver-
stained SDS-PAGE (Figure 1B, lanes 1–3). BCRP was purified
to more than 90% homogeneity visualized as an approximately
65 kDa full-length underglycosylated protein with no apparent
contaminating bands (Figure 1B, lanes 4–8). An immunoblot
confirmed that these bands were BCRP (data not shown).
Further purification by anion exchange chromatography was
precluded because the protein was thought to be sufficiently
pure. The overall yield of BCRP purified from 1.0 l yeast culture
was approximately 200 mg. This BCRP preparation was suitable
for electron crystallography by growing the crystals directly onStructure 18,the surface of an electron microscope (EM) grid, which requires
less protein (Rosenberg et al., 2005).
Purified BCRP in detergent solution was active in hydrolyzing
ATPwith a basal activity of approximately 20–60 nmol Pi/min/mg
protein (Figures 1C and 1D), which could be modulated by pra-
zosin (Figure 1E), a known BCRP substrate that has been shown
to stimulate BCRP ATPase activity (Glavinas et al., 2007).
This finding suggests that the purified BCRP remains correctly
folded in a nonreconstituted environment and the protein had
retained its activity through the purification process. The rela-
tively low basal ATPase activity of BCRP was likely due to
BCRP presenting in a nonreconstituted membrane environment,
but was in a similar range of the ATPase activity of BCRP purified
from insect cells (Pozza et al., 2006).
Two-Dimensional Crystals of BCRP in Different
Conformational States
Well-ordered 2D crystals of BCRPwere grown in the presence of
DDM as previously described (Rosenberg et al., 2005), except
that the crystals here were grown directly on the surface of
continuous carbon/molybdenum or carbon/gold grids at 4C.
In general, the crystals were larger and better ordered than the
P-gp crystals and thus more suitable for structure analysis by
electron crystallography (Figure 2). These crystals were some-
times 1.5 mm inwidth and 1.5 mm in length, and appeared visually
different to those of P-gp (Rosenberg et al., 2003) and CFTR
(Rosenberg et al., 2004), having less of a ‘‘honeycomb’’ and
a more of ‘‘square-shaped’’ appearance suggesting a different
space group compared with P-gp and CFTR (see below).
The crystals were grown in the presence or absence of 5 mMmi-
toxantrone by adding this drug to the appropriate crystallization
droplet.
The crystals were initially negatively stained, but to extend the
resolution of the data, cryo-EM was undertaken (Rosenberg
et al., 2005). Two different types of crystal forms were observed.
The calibrated unit cell parameters for the monoclinic type
crystal form in the absence of mitoxantrone were a = 57.3 ±
0.7 A˚ (n = 5), b = 88.0 ± 0.95 A˚ (n = 5), g = 89.7 ± 0.6 (n = 5),
while the other crystal form in the presence of mitoxantrone
measured a = 55.4 ± 0.6 A˚ (n = 5), b = 81.4 ± 1.1 A˚ (n = 5), g =
89.8 ± 0.5 (n = 5) (Table 1). In general, the crystals in the pres-
ence of the drug were larger and better ordered than the crystals
in the absence of the drug. This significant change in unit cell
dimensions, especially in the b direction, suggests that the
crystal packing has changed in the presence of mitoxantrone
and BCRP has adopted different conformations. Recent studies
for NhaA, the Na+/H+ exchanger from E. coli, also demonstrated
changes in unit cell dimensions concomitant with conformational
changes and showed that one crystal form was better ordered
than the other (Appel et al., 2009). The 2D crystals of BCRP
had a two-sided plane group p121 symmetry determined by
ALLSPACE (Valpuesta et al., 1994). Gamma (g) could have
been very slightly less than the required 90 degree angle for
this space group because of a slight crystal tilt on the electron
microscope grid for both mitoxantrone and non-mitoxantrone
crystal forms (Valpuesta et al., 1994). This space group is
different to that for P-gp and CFTR.
Low-dose images of frozen-hydrated crystals preserved in ice
showed strong reflections at 8 A˚ by optical diffraction. After482–493, April 14, 2010 ª2010 Elsevier Ltd All rights reserved 483
Figure 1. Expression, Purification, and ATPase Activity of BCRP
BCRP was expressed in Pichia pastoris and purified as described.
(A) Immunoblot of BCRP-enriched crude microsome membranes (20 mg of protein each lane) isolated from Pichia pastoris cells. Lanes 1, 3, and 4 indicate the
membrane preparations from different batches of cells expressing BCRP. Lane 2 represents the membranes prepared from the control cells with no BCRP
expression.
(B) Purification of BCRP by Ni2+-NTA affinity chromatographywasmonitored by analyzing protein samples on 10%SDS-PAGE followed by silver staining in lanes
1–4 and Coomassie blue staining in lanes 5–8. Lane 1, flow-through from Ni2+-NTA column (20 ml); lane 2, eluate from the first wash of Ni2+-NTA column with
resuspension buffer (20 ml); lane 3, eluate with 100 mM imidazole (20 ml); lanes 4–8, sequential fractions of eluates with 200 mM imidazole (20 ml each). Either
silver staining or Coomassie blue staining revealed a clearly enriched BCRP band at approximately 65 kDa in lanes 4 –8.
(C) ATPase activity measured at 37C with various amounts of purified BCRP in the absence of prozosin for 4 hr.
(D) Time-dependence of ATPase activity determined at 37C with 0.2 mg purified BCRP.
(E) The effect of prazosin at various concentrations on ATPase activity measured at 37C with 0.2 mg purified BCRP for 2 hr. Shown are means ± standard devi-
ations (SDs) of three independent determinations.
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Projection Structures of Human BCRP/ABCG2correction for lattice distortions, the crystals in the presence of
mitoxantrone yielded structure factors to 4.0 A˚ resolution
(Figure 3A). In the absence of mitoxantrone, the crystals were
slightly less well ordered; however, the corresponding deviation
map (see Figure S1 available online) of the 2D crystals with
vectors (magnified 203) between the perfect adapted lattice
and the actual unit cell positions suggests that thedrug-free crys-
tals are also well ordered, especially in the center of the crystals.
A plot of the phase quality shows that these crystals extend to 8 A˚
resolution (data not shown). For these crystals theMathewscoef-
ficient calculated with CCP4 (CCP4, 1994) suggested that there484 Structure 18, 482–493, April 14, 2010 ª2010 Elsevier Ltd All righwere 4 BCRP monomers (two BCRP dimers) in the asymmetric
unit cell assuming that the molecular mass of each BCRP
monomer was 65 kDa. McDevitt et al. (McDevitt et al., 2006)
reported a tetrameric 3D structure for BCRP purified from insect
cells in which different detergents were used for extraction
and purification of BCRP. It has been documented that the
association state of membrane proteins can depend on the
detergent used (Larue et al., 2009). However, both the projection
maps of this study and the previously reported 3D map could be
consistent with a tetrameric structure because the tetramer
would consist of four homodimeric BCRP molecules.ts reserved
Figure 2. Negatively Stained 2D Crystals of BCRP of the p121-Type Stained with 2% (w/v) Uranyl Acetate
Arrows indicate 2D crystals of BCRP of the p121 type in the absence of mitoxantrone. The 2D crystals of BCRP with mitoxantrone looked similar to those without
mitoxantrone (data not shown). Scale bar represents 123 nm. See also Figure S1.
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Projection Structures of Human BCRP/ABCG2Projection maps of 2D crystals of BCRP in the presence and
absence of mitoxantrone with data truncated at 5 A˚ resolution
and a p121 symmetry enforced were calculated after merging
data from six and five independent lattices, respectively (Fig-
ure 4). The overall average phase residual was 35 and 25
for the drug-free and drug-bound crystal forms, respectively
(Table 1). A single crystal image exhibited a screw axis,
providing confidence in the assignment of the space group
and the value of the Mathews coefficient. In both crystal forms,
the unit cell contains two BCRP homodimers related by a two-
fold screw axis along b with the dimer being present in alter-
nately up and down orientations. Each homodimer is
composed of two polypeptide chains related by a noncrystallo-
graphic two-fold axis of rotational symmetry. The BCRP mole-
cules were clearly delineated, but the packing of the dimers is
different in the two crystal forms. The BCRP dimers in the pres-
ence of mitoxantrone were rotated 20 relative to the no-drug
crystal form, resulting in a closer inter-dimer packing (Fig-
ure 4B). The introduction of additional close contacts between
the BCRP dimers presumably resulted in a better crystalline
order in the presence of the drug. Consequently, the shape
of the BCRP molecules was different between the two maps,
with the BCRP molecules having a more closed configuration
in the presence of mitoxantrone (Figure 4B) and a more open
shape in the absence of the drug (Figure 4A). A difference
map between the drug-free and drug-bound forms was calcu-
lated (Figure S2). The main changes appear to be a small solidStructure 18,body rotation around the crystal normal and, as implied by the
unit cell parameters, a compression of the structure in the pres-
ence of mitoxantrone. These data suggest that, in the presence
of mitoxantrone, BCRP has undergone a significant conforma-
tional change. This seems to fit with the interpretation in the
models of a drug-induced closing up of the transporter, which
has implications for the mechanisms of ABC transporters in
general (see below).
For X-ray structures of the bacterial ABC lipid transporter,
MsbA, trapped in different conformations, two nucleotide-bound
structures and two in the absence of nucleotide, were recently
reported (Ward et al., 2007). The two nucleotide-bound struc-
tures share the same outward-facing conformation, whereas
the two nucleotide-free apo structures have different inward-
facing conformations. The TMDs of MsbA are much closer in
the closed apo conformation than in the open apo conformation.
These authors suggested that the closed apo conformation
might represent an intermediate conformation between the
open apo and the nucleotide-bound outward-facing conforma-
tions, and that substrate binding to the open apo conformation
may promote the closure of the TMDs of MsbA, which would,
in turn, send a signal to the NBDs, allowing the formation of
the ATP sandwich upon nucleotide binding. The finding of this
study that the projection maps of BCRP display a more closed
conformation in the presence of mitoxantrone and a more
open shape in the absence of the drug appears to be consistent
with the structural data of MsbA.482–493, April 14, 2010 ª2010 Elsevier Ltd All rights reserved 485
Table 1. Crystallographic Image Processing Data for 2D Crystals
of BCRP
2D Crystals of BCRP in the Absence of Mitoxantrone
Two-sided plane
group symmetry
p121
Unit cell parameters a = 57.3 ± 0.7 A˚ (n = 5)
b = 88.0 ± 0.95 A˚ (n = 5)
g = 89.7 ± 0.6 (n = 5)
Number of crystals
used for merging
5
Number of
observations, IQa% 7
320
Overall phase
residual to 6 A˚, IQ% 5
35
Phase residual
Resolution range (A˚) Number of
observations
Phase residual
(random = 90)
200 – 18 24 38.9
20 – 14 13 34.6
15 – 9.5 42 38.2
10 – 8 32 36.7
8 – 5.5 70 27.9
5.5 – 5.1 30 37.7
2D crystals of BCRP in the presence of mitoxantrone
Two-sided plane
group symmetry
p121
Unit cell parameters a = 55.4 ± 0.6 A˚ (n = 5)
b = 81.4 ± 1.1 A˚ (n = 5)
g = 89.8 ± 0.5 (n = 5)
Number of crystals
used for merging
6
Number of
observations, IQ% 7
350
Overall phase
residual to 6 A˚, IQ% 5
25
Phase residual
Resolution range (A˚) Number of
observations
Phase residual
(random = 90)
200 – 18 20 37.3
20 – 14 19 40.9
15 – 10 24 32.7
10 – 7 35 35.0
7 – 5.5 42 33.3
5.5 – 4.1 37 21.0
a IQ is a measure of the signal/noise ratio of reflections.
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Projection Structures of Human BCRP/ABCG2Each BCRP monomer is predicted to contain 6 TM a helices
(Wang et al., 2008). In EM images obtained under cryocondi-
tions, the entire protein contributes to the information contained
in the images; thus, the extramembranous features as well as the
TM elements may be superimposed in EM projection maps.
Long a helices with axes close to the crystal normal could give
rise to strong 0.8–1 nm diameter features in the projection
map. At approximately 5 A˚ resolution, the spacing and dimen-
sions of some of the typical strong densities in the BCRP projec-486 Structure 18, 482–493, April 14, 2010 ª2010 Elsevier Ltd All rightion maps may be consistent with those of TM a helices
(Figure 4). The resolution of the projection maps is not sufficient
to interpret any of the densities as arising from re-entrant loops
such as those observed in aquaporin (Murata et al., 2000) or
those suggested to be present in bacterial transporters, neuro-
transmitter transporters, and ion exchanger antiporters (Slot-
boom et al., 1999; Wakabayashi et al., 2000).
Membrane Topology of BCRP
Although a high-resolution 3D structure of BCRP has not been
available, homology models of BCRP have been reported (Hazai
and Bikadi, 2008; Li et al., 2007). To further understand the
interactions between BCRP monomers in the 2D crystals, it
would be of value to fit homology models of BCRP to the projec-
tion maps we have obtained. However, the currently available
homology models do not appear to correctly predict the real
structure of BCRP as these models were based on the computer
prediction of BCRP topology structure, which is quite different
from the experimentally determined topology structure (see
below). Moreover, the currently available homology models
represent a substrate-free and nucleotide-bound conformation
of BCRP, which seems unsuitable to interpret the projection
structures of this study obtained with and without a substrate
in the absence of nucleotide. Therefore, we first performed rele-
vant homology modeling based on the topology structure of
BCRPwe recently determined (Wang et al., 2008). Amajor differ-
ence between the experimentally determined topology structure
and computer prediction is that the computer-predicted TM2
and TM5 are shifted to the extracellular and intracellular loops
in the experimental model, respectively (Wang et al., 2008). To
further confirm this significant shift, we generated additional
HA-tagged BCRP mutants using HA tag insertion mutagenesis,
one at a time, at positions immediately following the residues
435 (construct 435-HA), 445 (construct 445-HA), 460 (construct
460-HA), 470 (construct 470-HA), 540 (construct 540-HA), and
550 (construct 550-HA). Wild-type and HA-taggedmutant BCRP
were expressed in HEK cells by transit transfection. Immunoblot-
ting using the BXP-21 antibody detected wild-type BCRP and all
the mutants at comparable levels (Figure 5A). When immuno-
blotting was performed using a monoclonal antibody against
the HA tag, immunoreactive bands of approximately 75 kDa
were observed for all the mutants, but were absent for the vector
control or wild-type BCRP (Figure 5A). These results suggest
that all the HA-tagged BCRP mutants were well expressed in
HEK cells at levels comparable to wild-type BCRP. Immunofluo-
rescence analysis was then performed with intact cells or cells
that had been permeabilized with Triton X-100 to determine
extracellular or intracellular location of the HA tags, respectively.
No cell-based fluorescence was detected in intact or permeabi-
lized nontransfected control cells (data not shown) or in cells
expressing wild-type BCRP (Figure 5B). However, a strong
immunofluorescence signal was detected in both intact and
permeabilized cells expressing the mutants with HA tag inser-
tions at residues 435 (construct 435-HA) (Figure 5B, b and e)
and 445 (construct 445-HA) (Figure 5B, c and f), suggesting the
extracellular location of the HA tags at positions 435 and 445.
In contrast, cells expressing the mutants with HA tag insertion
at residues 540 (construct 540-HA) (Figure 5B, i and m) and
550 (construct 550-HA) (Figure 5B, j and n) showed brightts reserved
Figure 3. Diffraction Patterns of the BCRP Crystals
Shown are calculated Fourier transform amplitudes from the BCRP crystals after lattice unbending. The size of the squares and the numbers correspond to the IQ
value of the spots (Henderson et al., 1986). The rings depict the resolution bins. The axes give the directions of the reciprocal lattice vectors h and k. The left (A) and
the right (B) panels show the diffraction patterns of 2D crystals of BCRP in the presence and absence of 5 mM mitoxantrone, respectively. In the presence of
mitoxantrone, the data extended to 4 A˚ resolution in one direction.
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Projection Structures of Human BCRP/ABCG2fluorescence only in permeabilized cells, but not in intact nonper-
meabilized cells. This demonstrates the intracellular location of
the HA tags at positions 540 and 550. The fluorescence signal
associated with the mutants with HA tag insertion at residues
460 (construct 460-HA) (Figure 5B, g) and 470 (construct 470-
HA) (Figure 5B, h) was rather weak, and could be barely detected
only in permeabilized cells, suggesting that the HA tag at these
positions is located in a region with limited accessibility to the
antibody. Thus, the residues 460 and 470 are likely located in
a TM segment. For all the mutants, fluorescence staining was
mainly observed in the plasma membrane (Figure 5B), suggest-
ing that these mutants were predominantly targeted to the
plasma membrane of HEK cells. These immunoblotting and
confocal microscope data indicate that HA tag insertion in all
of the mutants does not appear to cause a major alteration in
BCRP structure that can affect protein stability, expression,
folding, and targeting to the plasma membrane. The mitoxan-
trone efflux activity of the mutants were approximately 11.7%,
3.6%, 4.2%, 15.3%, 9.7%, and 34.0% of wild-type BCRP
activity for constructs 435-HA, 445-HA, 460-HA, 470-HA,
540-HA, and 550-HA, respectively (data not shown). The activity
data indicate that, except for constructs 445 and 460, other
mutants retained at least partial transport activity, confirming
that sufficient amounts of these mutants were correctly folded
and targeted to the plasma membrane to exert efflux activity.
The decreased activities may reflect functional importance ofStructure 18,the positions at which the tag is inserted, rather thanmajor struc-
tural alterations. Taken together, these data further support the
topology structure of BCRP we previously reported (Wang
et al., 2008). As shown in Figure 5C, the residues 431–450 which
were predicted to be part of TM2 were now found to be in an
extracellular region, whereas residues 460, 462, and 470 that
were predicted in an intracellular loop were determined to be
in the TM2. The residues 562–582 predicted to be in an extracel-
lular loop were determined to form the TM5. The computer-pre-
dicted TM1, TM3, TM4, and TM6 are in correspondence with the
experimental data.
Homology Modeling of BCRP
Our earlier BCRP model (Hazai and Bikadi, 2008) was con-
structed using the Sav1866 structure (Dawson and Locher,
2006) as template and reflects the nucleotide-bound outward-
facing conformation. Owing to the low amino acid identity partic-
ularly in the TMDs among ABC transporters, the membrane
topology of BCRP used in our previous study was primarily
based on computer predictions. However, our experimental
data clearly indicate that there are crucial differences between
the predicted and the experimentally determined topology
structures. Except for two regions, the overall topology structure
of BCRP deduced from the experimental data is surprisingly
similar to that of P-gp observed in its X-ray structure (Aller
et al., 2009) (Figure 5C). First, the relatively large intracellular482–493, April 14, 2010 ª2010 Elsevier Ltd All rights reserved 487
Figure 4. Projection Maps of 2D Crystals of BCRP at 5 A˚ Resolution
Shown are projection maps of 2D crystals of BCRP at 5 A˚ resolution in the absence (A) and presence (B) of mitoxantrone under cryoconditions. One unit cell is
outlined by the boxes in the projection maps. The maps were calculated from merged amplitudes and phases from five or six independent lattices of crystals
embedded in vitreous ice drawn in p121. Dashed contours represent density below the mean, and solid contours represent density above the mean. The contour
interval is at about one-third of the root-mean-square density. Typical strong density peaks in the projection maps are evident (see Discussion). Scale bar repre-
sents 13 A˚. See also Figure S2.
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Projection Structures of Human BCRP/ABCG2loop connecting TM2 and TM3 that contains a coupling helix to
interact with the NBD of the same monomer as seen in the
X-ray structures of P-gp, Sav1866, and MsbA is missing in
BCRP. As a result, TM3 of BCRP is rather short and does not
intrude into the intracellular loop. Second, the extracellular
loop connecting TM5 and TM6 of BCRP is significantly longer
than the corresponding region in P-gp. Figure S3 shows
a multiple sequence alignment between the templates used for
homology modeling and BCRP based on the experimentally
determined topology. The order of TMD and NBD of the
templates was switched to reflect that of BCRP and the linker
region was deleted. The resulting sequence alignment suggests
that the number of gaps is considerably lower and the amino acid
identity in the TMD is much greater than that of sequence align-
ments solely based on TM computer predictions (Hazai and
Bikadi, 2008; Li et al., 2007). The overall amino acid identity
between the TMDs of BCRP and the first half of mouse P-gp is
approximately 18% without gaps. Furthermore, most of the
putative TM a helices of BCRP start and/or end with glycine or
proline (Figure 5C; Figure S3), similar to that observed for488 Structure 18, 482–493, April 14, 2010 ª2010 Elsevier Ltd All righP-gp. Residues that form the TMs are mostly hydrophobic,
whereas the intracellular and extracellular loops contain more
hydrophilic residues. The relative high amino acid identity in
the TMDs and the pattern of residue distribution suggest
a good quality of the sequence alignment. Li et al. (Li et al.,
2007) were unable to find adequate sequence identity between
P-gp and BCRP. This is likely due to themajor shifts in our exper-
imentally determined topology. For example, the large intracel-
lular loop connecting TM2 and TM3 in the computer-predicted
topology does not exist in our experimental topology model.
We found that, based on the experimental topology model, the
amino acid identity between the TMDs of P-gp and BCRP was
much improved.
The homology model using the MsbA structure as template
(Protein Data Bank [PDB] code 3B5W) (Ward et al., 2007) gener-
ated the substrate-unbound nucleotide-free apo inward-facing
conformation of BCRP (Figure 6A). The structure of the NBD is
well conserved among ABC transporters and has been exten-
sively discussed (Li et al., 2007), and thus is not further discussed
here. This dimeric model formed by 12 TM a helices possessests reserved
Figure 5. Analysis of Membrane Topology of BCRP by HA Tag Insertion and Immunofluorescence Confocal Microscopy as well as the
Topology Model of BCRP
(A) Immunoblots of whole cell lysates of HEK cells transfected with wild-type BCRP and HA-tagged BCRP mutant cDNA constructs 435-HA, 445-HA, 460-HA,
470-HA, 540-HA, and 550-HA. Whole cell lysates (30 mg protein each lane) were immunoblotted, and BCRP was detected with the BCRP-specific antibody
BXP-21 or a HA tag-specific antibody. b-actin expression was examined as an internal control. The vector control, wild-type BCRP, and the mutant constructs
are indicated above the blots.
(B) Immunofluorescence confocal micrographs. HEK cells were transiently transfected with wild-type BCRP and HA-tagged BCRP mutant cDNAs, probed with
the HA tag-specific antibody, and processed for fluorescence confocal microscopy. The HA-tagged BCRP signals are indicated in green. Exposure times were
identical for all the micrographs. The HA tags in constructs 435-HA (b, e) and 445-HA (c, f) were detected in both permeabilized (P) and intact, non-permeabilized
(NP) cells, whereas the HA tags in constructs 460-HA (g, k), 470-HA (h, l), 540-HA (i, m), and 550-HA (j, n) were detected only in permeabilized cells.
The correspondingmutant constructs are shown above themicrographs.Wild-type BCRP (a, d) was analyzed as a control. The experiments were repeated twice,
and similar results were obtained.
(C) The experimentally determined topology structure of BCRP as comparedwith that of mouse P-gp observed in its X-ray structure. Residues 387, 474, 529, 532,
540, 550, 560, and 651, and residues 420, 423, 435, 445, 454, 499, 502, 594, and 623 of BCRP were localized experimentally to the intracellular and extracellular
loops, respectively. Residues 460, 462, and 470 were localized in the TM2 segment. Similar to the template structures, most of the TM a helices of BCRP start
and/or end with glycine (GLY) or proline (PRO) as indicated. The length of TM a helices is indicated with the amino acid sequence numbers. The topologies of
BCRP and P-gp are similar, except that the intracellular loop connecting TM2 and TM3 is missing in BCRP and the extracellular loop connecting TM5 and TM6 of
BCRP is significantly larger than the corresponding region in P-gp.
Structure
Projection Structures of Human BCRP/ABCG2a wide open inward-facing structure that is closed from the
extracellular side. The entry of this open nucleotide-free
structure is large enough to allow access of a bulky of BCRP
substrates from either the inner leaflet or cytoplasm.Structure 18,Substrate-binding sites are likely located in the central cavity
surrounded by TM a helices. TM a helices are connected by
long intracellular or extracellular loops and extend far beyond
the membrane interface with the only exception of TM3. The482–493, April 14, 2010 ª2010 Elsevier Ltd All rights reserved 489
Figure 6. Homology Models of BCRP in the Open
(A) and Closed (B) Apo Inward-Facing Nucleotide-
free Apo Conformations
The models (A) and (B) were developed using the X-ray
structures of MsbA from E. coli and mouse P-gp as the
templates, respectively, as described. The open and
closed apo inward-facing structures represent a
substrate-free state and a substrate-bound state, respec-
tively. The TM a helices of each BCRP monomer are
labeled with numbers 1–6 in different colors. Individual
BCRP monomer is shown in red or blue. The putative
boundaries of the lipid bilayer are indicated with straight
lines. A coupling helix in the intracellular loop connecting
TM4 and TM5 of one BCRP monomer interacts with the
NBD of the opposite monomer. The dimensions of one
BCRP monomer are presented. See also Figure S3.
Structure
Projection Structures of Human BCRP/ABCG2extracellular loop connecting TM1 and TM2 forms intermonomer
contacts with residues in the extracellular loop connecting TM5
and TM6, and thus may contribute to stabilization of the dimeric
structure. In addition, intermonomer interactions between the
extracellular ends of the two centrally localized TM6 segments
can be seen, similar to that observed for P-gp in cross-linking
studies (Loo et al., 2003; Loo and Clarke, 1997). The unique
feature of this BCRP model (Figure 6A) is the missing of the
coupling helix 1 in the intracellular loop connecting TM 2 and
TM3, which is present in all of the available template structures
and could play a crucial role in the interactions between the
NBD and the TMD of the same monomer. The first 18 residues
at the NH2-terminus and residues 285–380 in the putative linker
region connecting the NBD to the TMD of BCRP could not be
modeled due to the lack of appropriate templates. This linker
region of BCRP is much longer than those of other ABC efflux
transporters and may serve as the coupling helix 1. Another
common feature that was revealed in the X-ray structures of
Sav1866, MsbA, and P-gp is that a second coupling helix
(coupling helix 2) crosses over and associates with the NBD of
the opposite monomer. This crossover motif is also present in
the homology model in the intracellular loop connecting TM4
and TM5, which may define the relative orientation of individual
domains and allow flexibility in the transporter (Figure 6A).
Glycine 553 in this region may be important for BCRP dimeriza-
tion (Polgar et al., 2006). Similar wide-open apo inward-facing
conformations have been shown in structures of other ABC
transporters (Chami et al., 2002; Hofacker et al., 2007; Ward
et al., 2007).
The second homology model of BCRP (Figure 6B) was devel-
oped based on the substrate-bound nucleotide-free structure of
mouse P-gp (PDB code: 3G60) (Aller et al., 2009). This model
represents the closed apo nucleotide-free inward-facing confor-
mation of BCRP that likely occurs in the catalytic cycle after
substrates enter thewide-open apo inward-facing conformation.
Comparing the open and closed nucleotide-free models, we
found that TM4 and TM5 of BCRP rotate 30 with a rotation
center at the extracellular side of the TMD near the putative
substrate-binding cavity. This rigid body motion is possibly490 Structure 18, 482–493, April 14, 2010 ª2010 Elsevier Ltd All rightransmitted to the NBDs by the coupling helix 2 and forces the
NBDs to close the wide-open entry from the intracellular side.
The distance between the two NBDs in the closed apo nucleo-
tide-free conformation, although becomes much shorter, still
does not allow direct interactions of the NBDs with each other.
The rotation also forces TMs 1 – 3 and 6 to similarly change their
positions. These conformational changes result in an intracel-
lular entry between the two TMDs in the closed apo structure
which is 20 A˚ narrower (a reduction from 90 A˚ to 70 A˚) as
compared with the open apo structure (Figure 6). Such a domain
rearrangement would alter the shape of the substrate-binding
cavity which is formed primarily by residues in the TMs by
making it more compact, thus allowing interactions of substrates
with both monomers at the same time. The results of homology
modeling are consistent with our experimental data of electron
crystallography. First, our EM data also demonstrated a similar
rotation of the projection structure of BCRP in the presence of
mitoxantrone (Figure 4). Second, such rotation also resulted in
a closer packing of the BCRP molecules in the presence of
mitoxantrone (Table 1). Taken together, both the EM data and
homology modeling suggest that the BCRP dimer could become
more compact upon substrate binding.
We further examined if the homology models of BCRP can
match with the densities in the corresponding projection maps.
This was performed by aligning two BCRP dimers of the models
related by a two-fold screw axis, which correspond to the p121
plane group symmetry of the 2D crystals, with the EM maps
using the Chimera program. In the drug-bound map, the TM
a helices align well with the high-density regions (Figures 7A–
7D). In the drug-free map, the larger tilt angles of TM a helices
appear to cause densities with more elongated areas (Figures
7E–7H). In both maps, two BCRP dimers cover the whole
unit cell. It is worth noting that the dimerization pattern of the
open apo model (Figure 7E–H) is similar to the oligomeric
structure of the open apo form of MsbA resolved in its X-ray
crystal structure (Ward et al., 2007) (PDB code 3B5W). Overall,
the fitting again suggests that our EM data and homology
modeling appear to be in good agreement. The fitting supports
the crystallographic data that the asymmetric unit cell in bothts reserved
Figure 7. Alignment of the BCRP Models with Projection Maps
(A) Two BCRP dimers of the closed apo model are related by a two-fold screw axis, corresponding to the p121 plane group symmetry of the 2D crystals in the
presence of mitoxantrone.
(B–D) A view of the fit of the two BCRP dimers in one unit cell of the projection map in the presence of mitoxantrone, from the bottom, the center, and the top of
the fit, respectively.
(E) Two BCRP dimers of the open apo model are related by a two-fold screw axis, corresponding to the p121 plane group symmetry of the 2D crystals in the
absence of mitoxantrone.
(F–H) A view of the fit of the two BCRP dimers in one unit cell of the projection map in the absence of mitoxantrone, from the bottom, the center, and the top of the
fit, respectively.
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Projection Structures of Human BCRP/ABCG2projection maps may accommodate two BCRP dimers. Indi-
vidual secondary structure elements (e.g., 12 TM a helices)
may not be clearly defined in the 2D projection maps. This is
because the BCRP molecule is not reconstituted in lipid and
we are uncertain whether the molecule is perpendicular to the
crystal plane. Also, in cryo projection maps, TM a helices,
NBDs, and underlying loops will be superimposed in the
structure (Kuo et al., 2005). Hence, only the overall densities
and shape of the BCRP models could be rationalized in the
projection maps by the fitting. For the same reasons, we did
not try to improve themodels by such fitting as this would require
a 3D map.
In conclusion, in the present study, we have described the
successful crystallization of the first well-diffracting 2D crystals
of BCRP at a resolution that provides significant structural infor-
mation. For the first time, we demonstrated the conformational
change of BCRP in the presence of its substrate drug, mitoxan-
trone. Homology modeling helped interpret the structural data.
Our resultsareconsistentwithmostof thebiochemical data avail-
able for BCRP. These structural data enhance our understanding
of thedrugbindingand transportmechanismofBCRPandestab-
lish a basis for further structure-function analyses of this impor-
tant drug transporter. The exact number of TMahelices, and their
relative orientations and assignment in the protein sequence,
cannot be resolved from the projection structures. This will
require the calculation of a 3Dmap, which is currently underway.Structure 18,EXPERIMENTAL PROCEDURES
Expression and Purification of BCRP in Pichia pastoris
Expression of BCRP in Pichia pastoriswas carried out as previously described
(Mao et al., 2004; Wu et al., 2005). Further details for expression and purifica-
tion of BCRP are described in the Supplemental Experimental Procedures.
Measurement of BCRP ATPase Activity
ATPase activity of purified BCRP was measured as described (Mao et al.,
2004). Further details can be found in the Supplemental Experimental
Procedures.
Two-Dimensional Crystallization, Electron Microscopy,
and Imaging Processing
The 2D crystals of BCRP were prepared essentially the same as previously
described (Rosenberg et al., 2005). BCRP (0.03 mg/ml) was incubated with
a mixture containing 10% (w/v) polyethylene glycol 4000, 100 mM ammonium
sulfate, 0.1% (w/v) DDM in Tris-HCl buffer (pH 7.4) with and without 5 mM
mitoxantrone for 17 hr at 4C. The sample was incubated with 300 mesh
gold or molybdenum grids coated with continuous carbon (TAAB Laboratories
Equipment Ltd, Berkshire, UK). The crystallization experiments were evaluated
by electron microscopy following negative staining in 2% (w/v) uranyl acetate.
The use of heavy metal gold or molybdenum grids is unlikely to have changed
the conformation of the protein because both were used for non-mitoxantrone
bound and mitoxantrone bound, and thus if they were eliciting an effect, we
would have seen this for the non-mitoxantrone-bound experiments. We saw
no additional conformational changes using a gold grid instead of a molyb-
denum grid and vice versa. Some specimens were frozen in liquid ethane
and subsequently transferred to a cryoholder cooled by liquid N2 to a tem-
perature of approximately 175C. Images were collected on a Tecnai F20482–493, April 14, 2010 ª2010 Elsevier Ltd All rights reserved 491
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Projection Structures of Human BCRP/ABCG2field-emission microscope at the University of Leeds at 200 keV at liquid N2
temperatures, magnification of 50,000 3, and mean underfocus ranging
from 4,000 to 15,000 A˚. Images were also collected on a FEI Tecnai G2 Polara
microscope (300 keV) at the University of Manchester with a Gatan CCD
camera and aCM200 at 200 keV equippedwith a Tietz CCD camera at Imperial
College, London. Images were recorded at 10–12 e/A˚2. Images were recorded
on Kodak SO-163 film and developed for 12 min in a full-strength Kodak D19
developer or recorded on CCD camera. We used the methods described in
the Supplemental Information to do the image processing with MRC and
2 dx software (Crowther et al., 1996; Gipson et al., 2006).
Determination of Membrane Topology of BCRP by Epitope Insertion
and Immunofluorescence
HA-tagged BCRP mutants with the HA (YPYDVPDYA) tags inserted, one at
a time, at positions immediately following the residues 435, 445, 460, 470,
540, and 550 were generated by epitope insertion mutagenesis. The
pcDNA3.1 constructs containing HA-tagged BCRP mutant cDNAs were con-
firmed by DNA sequencing and used for transient transfection into HEK293
cells. Expression of HA-tagged BCRPmutants was then analyzed by immuno-
blotting using the BCRP-specific antibody BXP-21 and the antibody against
the HA tag. The efflux activity of HA-tagged BCRP mutants and the location
of the HA tags with respect to the plasma membrane (intracellular or extracel-
lular) were determined using a flow cytometric efflux assay and immunofluo-
rescence confocal microscopy, respectively. When permeabilization of cells
was needed, 0.01% (v/v) Triton X-100 was used. All the above methods
were essentially the same as previously described (Wang et al., 2008).
Homology Modeling of BCRP
Based on the topology structure we determined (Wang et al., 2008), we per-
formed homology modeling to generate the open and closed apo nucleo-
tide-free conformations of BCRP. Primary sequence of human BCRP was
taken from the Universal Protein Resource (http://www.uniprot.org, accession
code: Q9UNQ0). Crystal structures of templates were obtained from the Broo-
khaven Protein Data Bank (http://www.rcsb.org/). The closed substrate-
bound inward-facing form of mouse P-gp (Aller et al., 2009) (PDB code:
3G60) and the open substrate-unbound inward-facing form of MsbA (Ward
et al., 2007) (PDB code: 3B5W) (both are nucleotide-free) were used as full-
length templates. MsbA was used as the template of the open substrate-
unbound inward-facing conformation of BCRP because the P-gp structure
in such a conformation has not been resolved. The topology of the outward-
facing nucleotide-bound form of Sav1866 (Dawson and Locher, 2006) (PDB
code: 2HYD) was also used in the refinement of sequence alignment.
TM boundaries of the templates used in sequence alignment were derived
from X-ray structures of the respective transporters. Two homology models
of BCRP were built with one representing the substrate-free open apo
inward-facing conformation based on MsbA and the other representing the
substrate-bound closed apo inward-facing conformation based on the mouse
P-gp structure. Further details can be found in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.str.2010.01.017.
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